Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Lands Late-Stage Enbrel Biosimilar In Deal With South Korea's Hanwha

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Merck & Co. has become a leader in the race to bring a low-cost version of Amgen's rheumatoid arthritis blockbuster Enbrel (etandercept) to the market after gaining rights to a late-stage biosimilar version of the biologic developed by South Korea's Hanwha Chemical Corporation
Advertisement

Related Content

Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma
Korea's Hanwha Chemical Leads With Enbrel Biosimilar - BIO Korea
Korea's Hanwha Chemical Leads With Enbrel Biosimilar - BIO Korea
Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)
Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)
PharmAsia News Presents: Notable Notes On Emerging Markets (Vol. 1, No. 2)
Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 2 of 2)
Asia Spotlight: Innovative, Differentiated Generics To Lead Merck Into Emerging Markets, Says EM President Kevin Ali
Innovative, Differentiated Generics To Lead Merck Into EMs, Says Merck EM President Kevin Ali; Prefer Partners Over Buyouts
Merck’s Ambitious Plans For Follow-On Biologics
Advertisement
UsernamePublicRestriction

Register

SC078202

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel